Pancreatic ductal adenocarcinoma remains a challenge to treat due to its complex biology and resistance mechanisms.

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...